Cytokinetics Closes $20M Round of Financing, Adds New Board Members

SOUTH SAN FRANCISCO, Calif.--Cytokinetics, a privately held biotechnology and informatics company here that is developing a cellular bioinformatics database based on cytoskeletal pharmacology, announced that it has completed a $20 million Series B Preferred Stock financing round. Investors included International Biomedicine Holdings, Microsoft co-founder Paul Allen's Vulcan Ventures, Duke University, and New Medical Technologies, Mayfield Fund, and Sevin Rosen Funds. Along with the funding, the company has added William Rutter, founder and former chairman of Chiron, and Stefan Ryser, partner of International Biomedicine Management Partners, to its board of directors.